Goldschmidt H, Lokhorst HM, Bertsch U, et al. Successful harvesting of peripheral hematopoietic stem cells after induction treatment with bort-ezomib, adriamycin, dexamethasone (PAD) in patients with newly diagnosed multiple myeloma(MM)[J]. Blood, 2008, 112: 3470.
[2]
Durie BG. Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival[J]. Cancer, 1975, 36(3): 842-854.
Adams J. The proteasome: a suitable antineoplastic target[J]. Nat Rev Cancer, 2004, 4(5): 349-360.
[7]
Hideshima T, Miltiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341[J]. Blood, 2003, 101(4): 1530-1534.
[8]
Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangi ogenesis in multiple myeloma via direct and indirect effects on endothelia1 cells[J]. Cancer Ras, 2006, 66(1): 184-191.
[9]
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Multiple Myeloma (V. 1. 2011). http: //www. nccn. org/peofessionals/physician_gle/PDF/myeloma. pdf.
Jesús F, San-Miguel JF, Mateos MV. How to treat a newly diagnosed young patient with multiple myeloma[J]. Hematology Am Soc Hematol Educ Program, 2009(1): 555-565.
[14]
Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial[J]. J Clin Oncol, 2010, 28(30): 4621-4629.
[15]
Corso A, Barbarano L, Mangiacavalli S, et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma[J]. Leuk Lymphoma, 2010, 51(2): 236-242.
